-
Alpha Innotech, a provider of bioanalytical systems for drug discovery and life science research, reported a product development and OEM supply agreement with R&C Biogenius (Los Angeles).
-
In today's microwave society, where results are sometimes wanted yesterday, coronary stent procedures have proven to be an amicable solution for treating diseased arteries.
-
Donald Wood has been named VP of operations for Abaxis (Union City, California), a manufacturer of portable blood analysis systems. Wood most recently served as VP of operations at Cholestech.
-
CVRx (Minneapolis) last month received the CE mark for its Rheos Baroreflex Hypertension Therapy System, which it said is the only implantable device designed to control hypertension.
-
Cardiogenesis (Irvine, Califonrnia), a developer of surgical products for transmyocardial revascularization (TMR) reported FDA approval of its PEARL (Port Enabled Angina Relief using Laser) 5.0 Robotic Delivery System.
-
-
It's a rather famous fact that patients frequently don't take the drugs they're prescribed and don't even have them filled at the pharmacy.
-
As surely as night follows day, the lawsuits began lining up against. Medtronic (Minneapolis) shortly after the reports of the company's recall of its Sprint Fidelis defibrillation leads in mid-October.
-
The era of second-generation drug-eluting stent (DES) technology moved one step closer to reality last month with a recommendation to the FDA by its cardiovascular system panel to approve the Endeavor DES from Medtronic (Minneapolis).
-
Largely at the prodding of industry, FDA has pondered whether it should grant device makers greater leeway in the use of clinical trials other than the gold standard of randomized, controlled trials (RCTs).
